Matthew Yglesias @mattyglesias
Gilead seems to have found a sweet spot with remdesivir where the existing trial is positive enough that everyone’s wants it and you won’t be able to put together a control group for future experiments even though as of now there’s no study of whether it saves lives or not. — PolitiTweet.org
